Sudo Biosciences Inc. has closed a $116 million series B financing, with the funding raised to be used to advance two investigational TYK2 candidates into the clinic in 2024.

Argenx SE CEO Tim Van Hauwermeiren said that, with subcutaneous efgartigimod (efgartigimod alfa and hyaluronidase-qvfc) in pemphigus, the company is “facing a situation where, even with a strong scientific hypothesis and well-executed trial, we encountered the unknown-unknown,” and the phase III experiment failed. “We are committed to doubling down” on the execution of the firm’s business plan, he added.

The data package for Filsuvez (birch triterpenes), a topical gel aimed at treating partial thickness wounds, satisfied U.S. reviewers the second time around. Chiesi Group said the FDA approved the treatment Dec. 19 for use in patients 6 months and older with rare blistering skin diseases junctional epidermolysis bullosa and dystrophic epidermolysis bullosa.

Samdolite Pharmaceuticals LLC has divulged prodrugs of cromoglicic acid reported to be useful for the treatment of inflammation and dermatological disorders.

Soltego Inc. has disclosed pyrimidopyrimidone compounds acting as serine/threonine-protein salt-inducible kinases (SIK) inhibitors reported to be useful for the treatment of erythematotelangiectatic and papulopustular rosacea.

Research at Nanjing Gritpharma Co. Ltd. has led to the identification of stilbene derivatives acting as aryl hydrocarbon receptor (AhR) agonists. As such, they are reported to be useful for the treatment of allergy, asthma, atherosclerosis, diabetes type 2, infections, osteoporosis, transplant rejection and graft-vs.-host disease.

Researchers from Guangdong University of Technology and collaborators recently published details on the preclinical characterization of GDU-952.